Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization

Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints, resulting in emergency use authorization/listing for several vaccines. However, given the short duration of follow-up during...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Minal K., Bergeri, Isabel, Bresee, Joseph S., Cowling, Benjamin J., Crowcroft, Natasha S., Fahmy, Kamal, Hirve, Siddhivinayak, Kang, Gagandeep, Katz, Mark A., Lanata, Claudio F., L'Azou Jackson, Maïna, Joshi, Sudhir, Lipsitch, Marc, Mwenda, Jason M., Nogareda, Francisco, Orenstein, Walter A., Ortiz, Justin R., Pebody, Richard, Schrag, Stephanie J., Smith, Peter G., Srikantiah, Padmini, Subissi, Lorenzo, Valenciano, Marta, Vaughn, David W., Verani, Jennifer R., Wilder-Smith, Annelies, Feikin, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2021
Materias:
Conference Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166525/
https://www.ncbi.nlm.nih.gov/pubmed/34119350
http://dx.doi.org/10.1016/j.vaccine.2021.05.099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166525/
https://www.ncbi.nlm.nih.gov/pubmed/34119350
http://dx.doi.org/10.1016/j.vaccine.2021.05.099

Ejemplares similares